Observational studyItalian journal of pediatrics2026
Changes in pediatric primary care contacts: has the RSV-immunization modified the age-related access?
Observational study in Italian journal of pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPrimary care is essential during children’s development, especially in the first years of life. Contacts with the Family Pediatricians (FP) always presented with seasonality, peaking in infants and toddlers. In Italy, nirsevimab was widely introduced in November 2024, potentially influencing the pattern of pediatric care utilization. This study aimed to evaluate temporal changes in FP contacts and the burden of bronchiolitis following nirsevimab introduction.
methodsA retrospective observational study has been conducted within Pedianet, an Italian primary-care network of FPs. Children residing in the Veneto region under five years of age and active between September 2022 and 2025 were included. All FP contacts were considered, identifying bronchiolitis-related visits and immunization ones. Age-specific incidence rates (IR) expressed in 100 person-months with 95% confidence intervals (CI) were calculated.
resultsA total of 25,399 children (median follow-up: 20.99 months) were included. Overall, 71.68 (95%CI:71.46–71.91) contacts per 100 person-months were recorded, showing clear seasonality with decreasing incidence while increasing age. After excluding immunization contacts, the difference in IRs between children in their first and second year of life was smaller in 2024/2025 than in 2023/2024, particularly in November (1-year:88.96 [95%CI:85.78–92.14] and 2-year:84.68 [95%CI:81.40–87.95] compared with 119.3 [95%CI:115.47–123.12] and 94.19 [95%CI:90.72–97.66]). Bronchiolitis burden among infants < 1 year declined from 6.58 (95%CI:5.70–7.47) to 1.24 (95%CI:0.87–1.62) contacts per 100 person-months in January 2024 and 2025, respectively, with a delayed seasonal peak in February 2025 (IR = 2.00, 95%CI:1.50–2.50).
conclusionsFollowing nirsevimab introduction, the burden of bronchiolitis markedly decreased, and differences in early-life contact rates narrowed. These findings support the need for adaptive pediatric care planning and continuous surveillance of respiratory disease trends accounting for preventive strategies implemented at the community level.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.